Tin tức & Cập nhật

Adjuvant nivolumab appears to improve survival outcomes in patients with muscle-invasive bladder cancer (MIBC) who have undergone radical surgery, regardless of prior exposure to neoadjuvant chemotherapy, according to additional data from the phase III CheckMate 274 trial.

The combination of the PARP inhibitor talazoparib plus the androgen receptor-pathway inhibitor enzalutamide yields a clinically meaningful increase in the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) being treated in the first-line setting when compared with enzalutamide alone, according to final data from the phase III TALAPRO-2 trial.

In the phase II pilot TRUCE-02 trial, tislelizumab plus low-dose nab-paclitaxel shows promising clinical antitumour activity and is well tolerated in patients with extensive very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy (RC).

The updated analysis of the phase III EV-302 trial continues to show the benefit of front-line enfortumab vedotin plus pembrolizumab (EV+P) compared with chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

Findings from a phase II trial demonstrate the potential of transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT) for men with metastatic (M1) prostate cancer who are on androgen receptor pathway inhibitors (ARPI).

The use of darolutamide (DARO) in addition to androgen deprivation therapy (ADT) is effective at improving radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared with placebo plus ADT, irrespective of disease volume, according to the subanalysis of the phase III ARANOTE trial.